TickerStat.com

Scribe Therapeutics, Inc. (SCTX)

Price—Loading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

2 annual periodsNewest to oldest
20252024
Revenue$51.2M$27.4M
Research & development$60.8M$57.1M
Operating income−$26.1M−$42.8M
Net income−$23.6M−$37.6M
Diluted EPSper diluted share-$8.98-$19.94
Review source filings at SEC.gov ↗

Insider buys & sells

Jul 1, 2024–Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)0$0.00 disclosed value
0 recent transactions
No insider transactions transactions were reported in the stored SEC coverage.
Review ownership filings at SEC.gov ↗